Myasthenia Gravis Clinical Trials in Portland, Oregon

5 studies are recruiting for myasthenia gravis in Portland, Oregon right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis

    This Phase 2 proof-of-concept, dose range finding study aims to evaluate the safety and efficacy of 3 dose levels of NMD670 vs placebo in adult patients with MG with antibodies against AChR or MuSK, administered twice a day (BID) for 21 days.

    Stage
    Phase 2
    Ages
    18 and older
    Site
    University of Oregon, Portland, Oregon
    Locations
    40 in total
    Run by
    NMD Pharma A/S

    See if you can join NCT06414954 on ClinicalTrials.gov

  2. KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis

    A Study of the Anti-CD 19 Chimeric Antigen Receptor T Cell Therapy for Patients with Myasthenia Gravis

    Stage
    Phase 2
    Ages
    18 to 75
    Site
    Oregon Health & Science University, Portland, Oregon
    Locations
    22 in total
    Run by
    Kyverna Therapeutics

    See if you can join NCT06193889 on ClinicalTrials.gov

  3. A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases

    A Phase 1 dose-escalation study designed to evaluate the safety, tolerability, and preliminary efficacy of anito-cel in subjects with generalized myasthenia gravis (GMG). Anitocabtagene autoleucel (anito-cel) is a BCMA-directed CAR-T cell therapy.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Oregon Health & Science University (OHSU), Portland, Oregon
    Locations
    13 in total
    Run by
    Arcellx, Inc.

    See if you can join NCT06626919 on ClinicalTrials.gov

  4. A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa

    This is a non-interventional, prospective, post authorization safety study. Patients with gMG who are expected to start treatment with efgartigimod at enrolment or are within their first cycle of efgartigimod at enrolment will be eligible to enroll into the efgartigimod cohort. Patients with gMG wh…

    Stage
    Not phased
    Ages
    18 and older
    Site
    Oregon Health and Science University, Portland, Oregon
    Locations
    35 in total
    Run by
    argenx

    See if you can join NCT06298565 on ClinicalTrials.gov

  5. The ME&MG Digital Solution for Autonomous Assessment of Myasthenia Gravis

    ME\&MG is a standalone software (digital solution) running on patients smartphones, connected to a web portal for physicians. It is intended to be used as an unsupervised digital self-assessment tool for the monitoring of disabilities in patients living with MG. ME\&MG contains digital active tests…

    Stage
    Not phased
    Ages
    18 and older
    Site
    OHSU, Portland, Oregon
    Locations
    19 in total
    Run by
    Ad scientiam

    See if you can join NCT05564936 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.